Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 11/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 8/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9298944 | 1.00 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL7890460 | 1.00 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL9298943 | 1.00 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL642482 | 1.00 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL7455717 | 1.00 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| Hydrochloric Acid SCHEMBL1357984 | 0.98 | GRIK1 (0.51) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| Bromide SCHEMBL7340598 | 0.98 | GRIK1 (0.51) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| Bromide SCHEMBL7340595 | 0.98 | GRIK1 (0.51) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL3186750 | 0.91 | GRIK1 (0.51) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL9299206 | 0.86 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389360-A2 | A PROCESS FOR THE PREPARATION OF ZOFENOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Glenmark Generics Limited (IN) | 2011-11-30 | — | — | EP | claimed |
| US-20110253651-A1 | Drying rack with wrap-around cover | BEHJAT MOHAMMAD KAZEM | 2011-10-20 | — | — | US | claimed |
| WO-2010084515-A2 | A PROCESS FOR THE PREPARATION OF ZOFENOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLENMARK GENERICS LIMITED (IN) | 2010-07-29 | — | — | WO | claimed |
| EP-1102745-B1 | A PROCESS FOR THE PREPARATION OF ZOFENOPRIL CALCIUM SALT | MENARINI INT OPERATIONS LU SA (LU) | 2004-05-12 | — | — | EP | claimed |
| US-6521760-B1 | Process for the preparation of zofenopril calcium salt | MENARINI RICHERCHE S.P.A. (IT) | 2003-02-18 | — | — | US | claimed |
| JP-2002522417-A | — | — | 2002-07-23 | — | — | JP | claimed |
| EP-1102745-A1 | A PROCESS FOR THE PREPARATION OF ZOFENOPRIL CALCIUM SALT | Menarini International Operations Luxembourg S.A. (LU) | 2001-05-30 | — | — | EP | claimed |
| WO-2000007984-A1 | A PROCESS FOR THE PREPARATION OF ZOFENOPRIL CALCIUM SALT | MENARINI RICERCHE S.P.A. (IT) | 2000-02-17 | — | — | WO | claimed |
| US-4482725-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR | E. R. SQUIBB & SONS, INC. (US) | 1984-11-13 | — | — | US | claimed |
| US-4325943-A | HYPOTENSIVE AGENTS, DIURETICS | E. R. SQUIBB & SONS, INC. (US) | 1982-04-20 | — | — | US | claimed |
| US-4284624-A | HYPOTENSIVE PEPTIDES | E. R. SQUIBB & SONS, INC. (US) | 1981-08-18 | — | — | US | claimed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-4325943-A | HYPOTENSIVE AGENTS, DIURETICS | E. R. SQUIBB & SONS, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| EP-0049589-A1 | Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-04-14 | — | — | EP | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
| US-4311705-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-19 | — | — | US | disclosed |
| US-4284624-A | HYPOTENSIVE PEPTIDES | E. R. SQUIBB & SONS, INC. (US) | 1981-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | GRIK1 3651/4885GRIA2 3962/4885CYP1A2 4845/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | GRIK1 3808/4885GRIA2 4564/4885CYP1A2 4648/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | GRIK1 3651/4885GRIA2 3962/4885CYP1A2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.